RGRobert A. Gilchick

Robert A. Gilchick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert A. Gilchick has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gonorrhea Screening Among Men Who Have Sex With Men: Value of Multiple Anatomic Site Testing, San Diego, California, 1997–2003

    by Robert A. Gunn, Catherine J. O’BRien, Marjorie A. Lee, Robert A. Gilchick

    The Centers for Disease Control and Prevention recommends that men who have sex with men (MSM) be screened annually for gonorrhea (GC) infection at the urethral, pharyngeal, or rectal site based on recent sexual exposure. This evaluation estimated the proportion of GC infections in MSM that would be missed if only urethral or urine specimens were tested. Culture of specimens from all sites and urethral (or urine) nucleic acid amplification test (NAAT) results for gonorrhea were reviewed for all identified MSM attending the San Diego County STD Clinic during 1997–2003. During the 7-year period, 7333 MSM were tested for GC and 1157 (15.8%) had a positive test result at ≥1 sites. Overall, 10.8% of urethral, 9.8% of rectal, and 4.0% of pharyngeal tests were positive. Among 5812 patients who had a urethral and a rectal or pharyngeal specimen tested, 970 were positive and among those, 369 (38%) had a negative test result in their urethral or urine specimen. Among 163 patients who had only a rectal and/or pharyngeal specimen tested for GC, 16 (9.8%) were positive. If the clinic had tested only urethral or urine specimens, 33% of total gonorrhea cases among MSM [385 (369 + 16) of 1157] would have been missed. GC screening strategies for MSM should include testing of rectal and pharyngeal specimens based on exposure. Given the decline of culture availability, efforts are needed to encourage laboratories to validate NAATs for rectal/pharyngeal specimens, which will likely increase exposure-based screening of MSM.


  • Syphilis Serologic Prevalence Monitoring Among STD Clinic Clients: Correlation With Reported Syphilis Incidence, San Diego, CA, 1985–2004

    by Robert A. Gunn, Marjorie Lee, Christina Oh, Stephanie Brodine

    Objective: To describe the serologic test for syphilis (STS) prevalence among STD clinic clients, determine the correlation between STS prevalence trends and reported community-diagnosed primary and secondary (P&S) case incidence, and evaluate the usefulness of STS prevalence monitoring as a component of syphilis surveillance. Study: During the period 1985–2004, 21,4336 STS were done among STD clinic clients and a variety of STS prevalence measures were evaluated. Results: From 1985–1991, 10.2% of STS were positive, which declined to 5.6% during 1992–2004. Overall, STS positivity (≥1:8) and male positivity (≥1:8) trends were correlated with reported community-diagnosed P&S case incidence and case incidence in men (r = 0.58 and r = 0.81, respectively). Male STS positivity (≥1:8) began increasing in 2001, 1 year before the increase in syphilis incidence in men, which began in the latter half of 2002 and occurred mostly among men who have sex with men. Conclusion: In a syphilis outbreak in men who have sex with men, STS prevalence (≥1:8) among male STD clinic clients was a useful measure of syphilis case incidence trends and may provide an early warning for a subsequent increase in community-diagnosed case incidence.


  • Hepatitis B Vaccination of Men Who Have Sex With Men Attending an Urban STD Clinic: Impact of an Ongoing Vaccination Program, 1998–2003

    by Marjorie A. Lee, Paula J. Murray, Robert A. Gilchick, Harold S. Margolis

    To evaluate the impact of an ongoing hepatitis B vaccination service offered in an urban sexually transmitted disease (STD) clinic. During the period 1998–2003, hepatitis B vaccine acceptance, series completion, and vaccine coverage rates were evaluated among men who have sex with men (MSM) and other clients attending the main STD clinic in San Diego County, California. Among 21,631 STD clinic attendees, 81% were eligible to start and 69% accepted hepatitis B vaccination. Among a cohort of MSM starting vaccination in 1998, 76% and 55% received 2 doses and 3 doses, respectively, after 1 year follow-up and coverage then increased 1–2 percentage points annually to a final 2-dose and 3-dose coverage of 80% and 62%, respectively. Vaccine coverage (≥1 prior vaccine dose) among STD clinic attendees in 2003 was 45% compared to only 11% in 1998, the first year of the program. Hepatitis B vaccination can be integrated into STD clinic services with reasonable levels of vaccine acceptance and series completion. The increase in vaccination coverage over time indicates that a sustained hepatitis B immunization program can achieve acceptable vaccine coverage in high-risk populations.


  • Partner Notification for Persons With Chronic Hepatitis B Virus Infection: Use of a Syphilis Model Service

    by Robert A. Gunn, Michelle S. Weinberg, Denise Borntrager, Paula J. Murray

    Adults with chronic hepatitis B virus (HBV) infection are usually the source of infection for persons who acquire sexually transmitted HBV infection. Vaccinating sex- and needle-sharing partners is recommended. To evaluate the usefulness of a syphilis model partner notification (PN) service for high-risk persons with chronic HBV infection. Locatable partners were offered serologic testing and HBV vaccination. Of 190 eligible case patients, 129 (68%) were interviewed, which included 47 men who have sex with men (MSM), 26 who reported injecting drug use (IDU), and 12 who were MSM and injected drugs. Among the 129 interviewed, 85 (66%) reported having =1 recent sex partner, 46 (36%) provided locating information for 47 partners, 38 partners accepted PN services, 15 were not immune, and 14 (7% of total eligible case patients) started and 9 completed the HBV vaccine series. Overall, 15% of case patients were also hepatitis C positive, and 29% were HIV infected. PN services cost was estimated at 1472 US dollars per vaccinee. High-risk persons with chronic HBV infection provided few names or locating information for their partners, and the proportion eligible for vaccination was low. An integrated approach that provides hepatitis C screening, human immunodeficiency virus testing, and referral might be more useful and should be evaluated.


  • Integrating Hepatitis, STD, and HIV Services into a Drug Rehabilitation Program

    by Robert A. Gunn, Marjorie A. Lee, David B. Callahan, Patricia Gonzales, Paula J. Murray, Harold S. Margolis


  • Surveillance for Repeat Gonorrhea Infection, San Diego, California, 1995???2001

    by Robert A. Gunn, Azarnoush Maroufi, Kimberly K. Fox, Stuart M. Berman

    Persons with repeat gonorrhea (GC) infection often participate in sexual networks that maintain and spread GC throughout the community. However, there are no established methods for collecting repeat GC surveillance data that are needed to monitor trends and risk factors for repeat infection. The goal of this study was to evaluate definitions and methods for establishing surveillance for repeat gonorrhea infection. During a 7-year period (1995–2001), all reported GC cases in San Diego County, California, were reviewed to identify persons with >2 GC infections that occurred >30 but <365 days apart. Various matching criteria and definitions of repeat infection were evaluated. Overall, 12,287 GC infections were reported; 509 persons accounted for 551 episodes of repeat infection and 9.7% of all GC infections. The mean annual repeat GC case rate was 2.8 per 100,000 population (range, 1.5–4.1) and repeat cases were 4.5% of total GC (range, 2.7–5.5%). Temporal trends in both repeat measures mirrored the overall county reported GC case rate. Young, inner-city males were more likely to have reported repeat GC infection. Simple, uniform repeat GC measures can be used to establish a surveillance system for monitoring trends, risk factors, and the impact of interventions directed toward preventing repeat GC infections.


  • Evaluation of Screening Criteria to Identify Persons With Hepatitis C Virus Infection Among Sexually Transmitted Disease Clinic Clients

    by Robert A. Gunn, Paula J. Murray, Carolyn H. Brennan, David B. Callahan, Miriam J. Alter, Harold S. Margolis

    The Centers for Disease Control and Prevention estimates that 1.8% of the US population is infected with hepatitis C virus (HCV), and most are unaware of their infection. The goal was to evaluate risk-based HCV screening criteria for clients attending an urban sexually transmitted disease (STD) clinic. This was a cross-sectional study of HCV prevalence among all STD clinic clients during an 8-month period (September 1999 through April 2000) in San Diego, California. HCV prevalence was 4.9% (165/3367). Clients who reported that they were injecting drug users (IDUs) were much more likely to be HCV-positive than other clients (51% versus 2%; P < 0.001). Selective screening of IDUs, sex partners of IDUs, and persons having received a blood transfusion before 1992 would have identified 70% of HCV-infected clients while screening only 12% of the clinic's attendees. The HCV prevalence among clients with a history of a bacterial STD (in the past 5 years) and no other major risk factors was only 2.5%. In STD clinics, integrating risk-based screening into routine clinic services is an efficient way to identify HCV-infected persons.